Akums Drugs and Pharmaceuticals Ltd
NSE:AKUMS
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| IN |
A
|
Akums Drugs and Pharmaceuticals Ltd
NSE:AKUMS
|
69B INR |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.1T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
212.1B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
154.9B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
79.2T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
35.6B CHF |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
279.2B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
37.6B USD |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
34.5B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
28.4B USD |
Loading...
|
|
| US |
|
Waters Corp
NYSE:WAT
|
22.9B USD |
Loading...
|
Market Distribution
| Min | -305 007.7% |
| 30th Percentile | 2.1% |
| Median | 5.8% |
| 70th Percentile | 11.6% |
| Max | 1 221 633.3% |
Other Profitability Ratios
Akums Drugs and Pharmaceuticals Ltd
Glance View
Akums Drugs and Pharmaceuticals Ltd., an unsung hero within India's healthcare sector, crafts its narrative through a robust commitment to pharmaceutical manufacturing. Founded in 2004, this company quietly emerged as a formidable provider of contract drug manufacturing solutions. Instead of marketing its own branded products, Akums positions itself as the silent partner behind many well-known pharmaceutical names, providing vital production services. By offering end-to-end manufacturing, from raw material sourcing to finished product packaging, Akums ensures that pharmaceutical companies can concentrate on their strengths: marketing and distribution. The company thrives on its vast portfolio, which encompasses the manufacture of nearly every form of a pharmaceutical product—be it tablets, capsules, injectables, or topical treatments. Akums drives revenue through partnerships, where it functions as the backbone of production lines for its clients. Utilizing cutting-edge technology and stringent global standards, Akums not only addresses the varied needs of the pharmaceutical industry but also adapts to the ever-evolving demands of healthcare worldwide. This strategic focus on high-quality contract manufacturing fuels its financial success, allowing it to expand facilities and scale operations, while maintaining a discreet presence that underscores its core philosophy: to innovate in service rather than spotlight.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Akums Drugs and Pharmaceuticals Ltd is 8.3%, which is in line with its 3-year median of 8.3%.
Over the last 0 months, Akums Drugs and Pharmaceuticals Ltd’s Net Margin has decreased from 8.3% to 8.3%. During this period, it reached a low of 8.3% on Jun 30, 2025 and a high of 8.3% on Jun 30, 2025.